Literature DB >> 21532064

Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement.

Nodoka Sakurai, Kazushige Nagai, Hiroyuki Tsutsumi, Shingo Ichimiya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21532064     DOI： 10.3899/jrheum.101220

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  6 in total

Review 1.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

2.  Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.

Authors:  Yun Peng; Suhan Zhang; Yi Zhao; Yi Liu; Bing Yan
Journal:  Clin Rheumatol       Date:  2017-08-25       Impact factor: 2.980

3.  Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.

Authors:  Sara Sabbagh; Iago Pinal-Fernandez; Lisa G Rider; Andrew Lee Mammen; Takayuki Kishi; Ira N Targoff; Frederick W Miller
Journal:  Ann Rheum Dis       Date:  2019-04-24       Impact factor: 19.103

Review 4.  Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.

Authors:  Ilaria Pagnini; Antonio Vitale; Carlo Selmi; Rolando Cimaz; Luca Cantarini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 10.817

5.  Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?

Authors:  Satoshi Ikeda; Machiko Arita; Mitsunori Morita; Satoshi Ikeo; Akihiro Ito; Fumiaki Tokioka; Maki Noyama; Kenta Misaki; Kenji Notohara; Tadashi Ishida
Journal:  BMC Pulm Med       Date:  2015-12-09       Impact factor: 3.317

6.  KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Authors:  Tao Zhang; Ping Shen; Chunyan Duan; Lingyun Gao
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.